(Q33677560)

28 July 2017

title

Absence of effect of stimulants on the phamacokinetics of desipramine in children (English)

1 reference

28 July 2017

5

1 reference

28 July 2017

3

Biederman J

1 reference

28 July 2017

Cohen LG

1

1 reference

28 July 2017

Prince J

2

1 reference

28 July 2017

Wilens T

4

1 reference

28 July 2017

Whitt S

6

1 reference

28 July 2017

Mick E

7

1 reference

28 July 2017

Spencer T

8

1 reference

28 July 2017

Meyer MC

9

1 reference

28 July 2017

Polisner D

10

1 reference

28 July 2017

Flood JG

11

1 reference

28 July 2017

language of work or name

English

0 references

publication date

1 June 1999

1 reference

28 July 2017

1 reference

28 July 2017

volume

19

1 reference

28 July 2017

issue

6

1 reference

28 July 2017

page(s)

746-752

1 reference

Predicting desipramine levels in children and adolescents: a naturalistic clinical study

28 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.9.746.31539

Methylphenidate and desipramine in hospitalized children: I. Separate and combined effects on cognitive function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.9.746.31539

Nortriptyline treatment of children with attention-deficit hyperactivity disorder and tic disorder or Tourette's syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.9.746.31539

Developmental Changes in Serum Concentrations of Desipramine and 2-Hydroxydesipramine during Treatment with Desipramine

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.9.746.31539

Nortriptyline in the treatment of ADHD: a chart review of 58 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.9.746.31539

Adolescent suicidality in urban minorities and its relationship to conduct disorders, depression, and separation anxiety

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.9.746.31539

A double-blind placebo controlled study of desipramine in the treatment ADD: II. Serum drug levels and cardiovascular findings

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.9.746.31539

Antidepressant treatments in children and adolescents: II. Anxiety, physical, and behavioral disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.9.746.31539

Behavioral, situational, and temporal effects of treatment of ADHD with methylphenidate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.9.746.31539

Differential Effects of Methylphenidate on Working Memory in ADHD Children with and without Comorbid Anxiety

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.9.746.31539

Side effects of methylphenidate and dexamphetamine in children with attention deficit hyperactivity disorder: a double-blind, crossover trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.9.746.31539

A potential clinical use for methylphenidate with tricyclic antidepressants.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.9.746.31539

Clinical and metabolic studies with imipramine in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.9.746.31539

Cardiovascular effects of therapeutic doses of tricyclic antidepressants in children and adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.9.746.31539

Desipramine clearance in children and adolescents: absence of effect of development and gender.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.9.746.31539

Pharmacokinetic variability in the adolescent: implications of body size and organ function for dosage regimen design

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.9.746.31539

Clinical pharmacokinetics of imipramine and desipramine

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.9.746.31539

Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.9.746.31539

Relationship of in vitro data on drug metabolism to in vivo pharmacokinetics and drug interactions: implications for diazepam disposition in humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.9.746.31539

Pathways of metabolism of amphetamine and related compounds

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.9.746.31539

Steady-state plasma concentrations of imipramine and desipramine in relation to S-mephenytoin 4'-hydroxylation status in Japanese depressive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.9.746.31539

Recent developments in hepatic drug oxidation. Implications for clinical pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.9.746.31539

Selective serotonin reuptake inhibitors and CNS drug interactions. A critical review of the evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.9.746.31539

Pharmacogenetics in pediatrics. Implications for practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.9.746.31539

Tricyclic antidepressant and methylphenidate treatment of attention deficit disorder in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.9.746.31539

Combined pharmacotherapy: an emerging trend in pediatric psychopharmacology

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.9.746.31539

Side effects of methylphenidate and desipramine alone and in combination in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.9.746.31539

Suicidal adolescents after hospitalization: parent and family impacts on treatment follow-through

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.9.746.31539

First-pass metabolism of imipramine and desipramine: Impact of the sparteine oxidation phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.9.746.31539

Sudden death in children treated with a tricyclic antidepressant

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.9.746.31539

Case study: two additional sudden deaths with tricyclic antidepressants

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.9.746.31539

The clinician and drug interactions--an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.9.746.31539

Inhibition of alprazolam and desipramine hydroxylation in vitro by paroxetine and fluvoxamine: comparison with other selective serotonin reuptake inhibitor antidepressants

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.9.746.31539

Extensive and enantioselective presystemic metabolism of dl-threo-methylphenidate in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.9.746.31539

Temporal relationships between the pharmacokinetics of methylphenidate in the human brain and its behavioral and cardiovascular effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.9.746.31539

Amphetamine metabolism in amphetamine psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.9.746.31539

Desipramine pharmacokinetics when coadministered with paroxetine or sertraline in extensive metabolizers

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.9.746.31539

Polymorphic 2-hydroxylation of desipramine. A population and family study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.19.9.746.31539

10.1592/PHCO.19.9.746.31539

21 January 2018

Identifiers

DOI

1 reference

28 July 2017

1 reference